This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Department of Pharmacy, Iowa City Veterans Affairs Health Care System, Iowa City, Iowa
  2. Corresponding Author: Delaney R. Brainerd, PharmD, Iowa City VA Health Care System (Mailstop 119), 601 Hwy 6 W, Iowa City, IA 52246 ([email protected]).
  3. Center for Access & Delivery Research and Evaluation, Iowa City Veterans Affairs Health Care System, Iowa City, Iowa
  4. Department of Pharmacy, Iowa City Veterans Affairs Health Care System, Iowa City, Iowa
  5. Center for Access & Delivery Research and Evaluation, Iowa City Veterans Affairs Health Care System, Iowa City, Iowa
  6. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa
  1. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39–60. PubMed CrossRef
  2. Wagner E, Siafis S, Fernando P, et al. Efficacy and safety of clozapine in psychotic disorders – a systematic quantitative meta-review. Transl Psychiatry. 2021;11(1):487. PubMed
  3. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. PubMed CrossRef
  4. Iqbal E, Govind R, Romero A, et al. The side effect profile of clozapine in real world data of three large mental health hospitals. PLoS One. 2020;15(12):e0243437. PubMed CrossRef
  5. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477–2482. PubMed CrossRef
  6. Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®. Psychol Med. 2021;51(9):1459–1466. PubMed
  7. Tiihonen J, Tanskanen A, Bell JS, et al. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry. 2022;9(5):353–362. PubMed CrossRef
  8. Dawson JL, Sluggett JK, Procter NG, et al. Hematological and other cancers in people using clozapine: analysis of Australian spontaneous reports between 1995 and 2020. J Clin Psychopharmacol. 2023;43(4):333–338. PubMed CrossRef
  9. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. Accessed April 27, 2023. https://www.whocc.no/atcddd/indexdatabase
  10. Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. PubMed CrossRef
  11. Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
  12. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull. 2019;45(2):315–329. PubMed CrossRef
  13. Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. PubMed CrossRef
  14. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. PubMed CrossRef
  15. US Department of Veterans Affairs. Veterans’ diseases associated with Agent Orange. Accessed March 19, 2023. https://www.publichealth.va.gov/exposures/agentorange/conditions/index.asp
  16. Nooka AK, Lonial S, Boise LH, et al. Risk factors for development of myeloma: role of smoking and alcohol. Blood. 2014;124(21):2604.
  17. de Leon J, De Las Cuevas C, Sanz EJ, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):537–538. PubMed
  18. Schulte PF, Cohen D, Veerman SR, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):538–539. PubMed CrossRef